NASDAQ:KTTA Pasithea Therapeutics Q2 2026 Earnings Report $0.44 0.00 (-0.81%) Closing price 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pasithea Therapeutics EPS ResultsActual EPS-$0.16Consensus EPS -$0.16Beat/MissMet ExpectationsOne Year Ago EPSN/APasithea Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.30 millionBeat/MissN/AYoY Revenue GrowthN/APasithea Therapeutics Announcement DetailsQuarterQ2 2026Date8/14/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time7:00AM ETUpcoming EarningsPasithea Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Pasithea Therapeutics Earnings HeadlinesPasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European ...September 14, 2026 | finance.yahoo.comPasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis ConferenceSeptember 14, 2026 | globenewswire.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 7 at 1:00 AM | Reagan Gold Group (Ad)Pasithea Therapeutics Announces Participation in Two September 2026 Investor ConferencesSeptember 3, 2026 | globenewswire.comPasithea Therapeutics Corp KTTAAugust 15, 2026 | morningstar.comMPasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026July 21, 2026 | globenewswire.comSee More Pasithea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email. Email Address About Pasithea TherapeuticsPasithea Therapeutics (NASDAQ:KTTA) is a biotechnology company focused on developing treatments for central nervous system disorders and other serious diseases. The company’s research has included novel pharmaceutical therapies as well as psychedelic- and ketamine-assisted treatment approaches for conditions such as depression and other mental health disorders. Pasithea’s development portfolio has included PAS-004, an orally administered MEK1/2 inhibitor designed to affect the RAS/MAPK signaling pathway. The company has pursued potential applications for this type of therapy in oncology and other diseases involving abnormal cellular signaling, while continuing to evaluate opportunities in neuroscience. Historically, Pasithea also operated or planned ketamine treatment clinics in the United States and the United Kingdom and conducted research involving psychedelic medicines. The company was founded in 2020, with neuroscientist and psychiatrist Dr. Tiago Reis Marques serving as a key member of its founding leadership.View Pasithea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Penguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry Point Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
